Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Cyclospora parasite illnesses have affected 28 NC counties, sickened more than 200 people
Recommended
Back to school guide: Buses, lunches, key dates
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
37.25
-0.37 (-0.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
August 08, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
August 08, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
August 07, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Where Apellis Pharmaceuticals Stands With Analysts
August 03, 2023
Via
Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 07, 2023
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...
Via
Benzinga
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
August 07, 2023
The company is already under scrutiny after reports of side effects tied to Syfovre.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 07, 2023
Via
Benzinga
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $750,000 to Contact the Firm
August 06, 2023
Via
ACCESSWIRE
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS
August 06, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APELLIS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
August 04, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS
August 03, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Apellis Pharmaceuticals, Inc. (APLS)
August 03, 2023
From
Robbins LLP
Via
Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS
August 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
August 03, 2023
Via
Benzinga
APLS Investor Alert: Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce the Filing of a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
August 02, 2023
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
August 01, 2023
On Tuesday, 46 stocks hit new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2023
August 01, 2023
Via
Benzinga
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
July 31, 2023
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.
Via
Benzinga
Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales Beat
July 31, 2023
Apellis crashed after Syfovre safety issues continued to plague the stock.
Via
Investor's Business Daily
Stocks That Hit 52-Week Lows On Monday
July 31, 2023
On Monday, 27 stocks hit new 52-week lows.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 31, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
July 31, 2023
Via
Benzinga
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
July 31, 2023
Via
Benzinga
Apellis Pharmaceuticals Stock Slips Despite Q2 Sales Beat Thanks To Syfovre, Empaveli
July 31, 2023
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported a second quarter (Q2) EPS loss of $1.02, beating the
Via
Benzinga
Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
July 31, 2023
Gainers
Via
Benzinga
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
July 31, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
July 30, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For July 31, 2023
July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.
Via
Benzinga
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
July 29, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.